
Opinion|Videos|December 16, 2024
Spesolimab Efficacy Data
Key Takeaways
Panelists discuss how the efficacy data from the Effisayil 2 trial demonstrate that spesolimab significantly delayed the time to first GPP flare and reduced flare severity, highlighting its potential as an effective treatment for preventing life-threatening flares in GPP patients.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
New Consensus Defines Remission, Disease Activity in Atopic Dermatitis
2
Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis
3
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
4
Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate
5












